X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (857) 857
humans (682) 682
female (459) 459
male (417) 417
phthalazines - administration & dosage (398) 398
animals (392) 392
phthalazines - pharmacology (351) 351
phthalazines - therapeutic use (316) 316
adult (254) 254
middle aged (236) 236
oncology (226) 226
mice (180) 180
pharmacology & pharmacy (172) 172
aged (156) 156
phthalazines - adverse effects (152) 152
rats (144) 144
cancer (139) 139
piperazines - administration & dosage (136) 136
cell line, tumor (128) 128
treatment outcome (120) 120
poly polymerase (115) 115
administration, intranasal (109) 109
piperazines - pharmacology (108) 108
azelastine (102) 102
double-blind method (99) 99
piperazines - therapeutic use (98) 98
olaparib (95) 95
adolescent (93) 93
rhinitis, allergic, seasonal - drug therapy (92) 92
ovarian neoplasms - drug therapy (90) 90
administration, oral (88) 88
phthalazines - pharmacokinetics (88) 88
dose-response relationship, drug (87) 87
antineoplastic agents - therapeutic use (86) 86
ovarian cancer (83) 83
chemotherapy (82) 82
mutation (80) 80
allergy (79) 79
poly polymerase inhibitors (77) 77
breast cancer (74) 74
inhibition (74) 74
tumors (72) 72
aldehyde reductase - antagonists & inhibitors (69) 69
antineoplastic combined chemotherapy protocols - therapeutic use (69) 69
dna damage (68) 68
analysis (66) 66
poly polymerase inhibitors - pharmacology (66) 66
xenograft model antitumor assays (65) 65
abridged index medicus (64) 64
dna repair (64) 64
immunology (63) 63
ovarian neoplasms - genetics (63) 63
angiogenesis (62) 62
anti-allergic agents - administration & dosage (60) 60
histamine h1 antagonists - administration & dosage (60) 60
histamine h1 antagonists - therapeutic use (60) 60
antineoplastic agents - pharmacology (59) 59
expression (59) 59
homologous recombination (59) 59
anti-allergic agents - therapeutic use (58) 58
phthalazines - chemistry (58) 58
therapy (58) 58
parp inhibitor (57) 57
care and treatment (56) 56
chemistry, medicinal (56) 56
mice, nude (56) 56
poly polymerase inhibitors - administration & dosage (56) 56
allergic rhinitis (55) 55
research (55) 55
time factors (55) 55
brca1 protein - genetics (54) 54
cells (54) 54
child (54) 54
double-blind (54) 54
poly polymerases - metabolism (54) 54
piperazines - adverse effects (53) 53
pyridines - administration & dosage (53) 53
cell proliferation - drug effects (52) 52
efficacy (52) 52
disease models, animal (50) 50
rhinitis, allergic, perennial - drug therapy (50) 50
drug synergism (48) 48
enzyme inhibitors - pharmacology (48) 48
neoplasms - drug therapy (48) 48
apoptosis - drug effects (47) 47
medicine & public health (47) 47
pyridines - pharmacology (47) 47
brca2 protein - genetics (46) 46
deoxyribonucleic acid--dna (46) 46
endothelial growth-factor (46) 46
antineoplastic agents - administration & dosage (45) 45
article (45) 45
safety (45) 45
antineoplastic combined chemotherapy protocols - pharmacology (44) 44
biochemistry & molecular biology (44) 44
breast neoplasms - drug therapy (44) 44
drug therapy (43) 43
histamine h1 antagonists - pharmacology (43) 43
poly polymerase inhibitors - therapeutic use (43) 43
apoptosis (42) 42
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (877) 877
Japanese (9) 9
French (7) 7
Russian (7) 7
German (6) 6
Chinese (3) 3
Polish (3) 3
Czech (2) 2
Hungarian (1) 1
Italian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 852 - 861
Summary Background Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | BRCA2 MUTATIONS | LIPOSOMAL DOXORUBICIN | RIBOSE POLYMERASE INHIBITORS | SOLID TUMORS | ONCOLOGY | GENETICS | GUIDELINES | SENSITIVITY | RESISTANCE | PARP INHIBITOR | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carcinoma - mortality | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Time Factors | Aged, 80 and over | Cell Differentiation | Carcinoma - drug therapy | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Administration, Oral | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Canada | Breast Neoplasms - genetics | Carcinoma - genetics | Mutation | Receptor, ErbB-2 - analysis | Piperazines - administration & dosage | Receptors, Estrogen - analysis | Ovarian Neoplasms - mortality | Breast Neoplasms - enzymology | Antineoplastic Agents - adverse effects | Carcinoma - enzymology | Adult | Female | Ovarian Neoplasms - drug therapy | Carcinoma - secondary | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Treatment Outcome | BRCA1 Protein - genetics | Disease-Free Survival | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | BRCA2 Protein - genetics | Phthalazines - adverse effects | Care and treatment | Relapse | Gene mutations | Oncology, Experimental | Breast cancer | Research | Cancer | Diseases | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3, pp. 244 - 250
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2012, Volume 18, Issue 8, pp. 2344 - 2351
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 6, pp. dju089 - dju089
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2017, Volume 23, Issue 12, pp. 3097 - 3108
Purpose: PARP inhibition (PARPi) has modest clinical activity in recurrent BRCA-mutant (BRCA(MUT)) high-grade serous ovarian cancers (HGSOC). We hypothesized... 
OLAPARIB | THERAPY | RANDOMIZED PHASE-2 | CHK1 | ONCOLOGY | PHOSPHORYLATION | SYNTHETIC LETHALITY | CELL-CYCLE | CHECKPOINT | REPLICATION FORK COLLAPSE | ATR | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Humans | Checkpoint Kinase 1 - antagonists & inhibitors | Ovarian Neoplasms - pathology | Molecular Targeted Therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Ovarian Neoplasms - genetics | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Sulfoxides - administration & dosage | Pyrazoles - administration & dosage | Animals | Ataxia Telangiectasia Mutated Proteins - antagonists & inhibitors | Cell Line, Tumor | Genomic Instability - drug effects | Female | Cell Proliferation - drug effects | Mice | Ovarian Neoplasms - drug therapy | Ovarian carcinoma | G2 phase | Genomes | Ovarian cancer | Genomic instability | Quality | Cell cycle | Xenografts | Remission | Inhibition | Cell survival | Stability | BRCA1 protein | Colonies | CHK1 protein | Regression | Poly(ADP-ribose) polymerase | Breast cancer | Stability analysis | Regression analysis | Survival | Experimental design | Cell death | Aberration | Chromosome aberrations | Cancer | Apoptosis | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1207 - 1214
Summary Background Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1,... 
Hematology, Oncology and Palliative Medicine | TRIAL | POLY(ADP-RIBOSE) POLYMERASE | ONCOLOGY | BEVACIZUMAB | DOWN-REGULATION | FALLOPIAN-TUBE | OPEN-LABEL | EPITHELIAL OVARIAN | MAINTENANCE THERAPY | PRIMARY PERITONEAL | NEGATIVE BREAST-CANCER | Piperazines - administration & dosage | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Neoplasms, Glandular and Epithelial - mortality | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Risk Assessment | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Carcinoma, Ovarian Epithelial | Aged | Women | Antimitotic agents | Relapse | Oncology, Experimental | Research | Antineoplastic agents | Vascular endothelial growth factor | Sugars | Cancer | Diseases | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
Journal Article
Journal of Aerosol Medicine and Pulmonary Drug Delivery, ISSN 1941-2711, 06/2016, Volume 29, Issue 3, pp. 233 - 241
Background: In allergen-induced asthma, activated mast cells start the lung inflammatory process with degranulation, cytokine synthesis, and mediator release.... 
pharmacokinetics | jet mill | dust feed | lung function | inhaled therapy | pre-clinical | LUNG | ACTIVATION | LATE RESPONSES | DEPOSITION | RATS | BRUTONS TYROSINE KINASE | INTRATRACHEAL INSTILLATION | INTERNALIZATION | RESPIRATORY SYSTEM | MICE | MAST-CELL DEGRANULATION | Glucocorticoids - administration & dosage | Pneumonia - physiopathology | Bronchial Hyperreactivity - immunology | Bronchodilator Agents - administration & dosage | Protein-Tyrosine Kinases - metabolism | Humans | Male | Lung - enzymology | Bronchoconstriction - drug effects | Asthma - immunology | Pneumonia - immunology | Anti-Inflammatory Agents - administration & dosage | Disease Models, Animal | Protein Kinase Inhibitors - pharmacokinetics | Dry Powder Inhalers | Phthalazines - administration & dosage | Asthma - physiopathology | Pneumonia - enzymology | Asthma - enzymology | Lung - physiopathology | Mast Cells - enzymology | Protein Kinase Inhibitors - administration & dosage | B-Lymphocytes - immunology | Lung - drug effects | Pyridazines - pharmacokinetics | Mice, Inbred BALB C | Budesonide - administration & dosage | Immunoglobulin G - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Phthalazines - pharmacokinetics | Pneumonia - prevention & control | Dose-Response Relationship, Drug | Anti-Asthmatic Agents - pharmacokinetics | Immunoglobulin G - immunology | Prostaglandin D2 - metabolism | Bronchial Hyperreactivity - physiopathology | Albuterol - administration & dosage | Pyridazines - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Cytokines - immunology | Mast Cells - immunology | Ovalbumin | B-Lymphocytes - enzymology | Cytokines - metabolism | Cells, Cultured | Administration, Inhalation | Bronchial Hyperreactivity - prevention & control | Asthma - drug therapy | Mast Cells - drug effects | B-Lymphocytes - drug effects | Bronchial Hyperreactivity - enzymology | Animals | Bronchodilator Agents - pharmacokinetics | Prostaglandin D2 - immunology | Adrenergic beta-2 Receptor Agonists - administration & dosage | Anti-Asthmatic Agents - administration & dosage | Lung - immunology | Cell Degranulation - drug effects
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 13, pp. 3405 - 3415
Purpose: Both PARP inhibitors (PARPi) and sacituzumab govitecan (IMMU-132) are currently under clinical evaluation in triple-negative breast cancer (TNBC). We... 
POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | SACITUZUMAB GOVITECAN IMMU-132 | REPAIR | ONCOLOGY | DNA-DAMAGE | IRINOTECAN | HOMOLOGOUS RECOMBINATION | CELL-LINES | COMBINATION | PHASE-I | Piperazines - administration & dosage | Synthetic Lethal Mutations - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Gene Expression Regulation, Neoplastic | Immunoconjugates - administration & dosage | Indoles - administration & dosage | Triple Negative Breast Neoplasms - immunology | Immunoconjugates - immunology | Antibodies, Monoclonal, Humanized - administration & dosage | DNA Topoisomerases, Type I - drug effects | Triple Negative Breast Neoplasms - pathology | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | DNA Repair - drug effects | Phthalazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - immunology | Triple Negative Breast Neoplasms - therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Drug Resistance, Neoplasm - genetics | Animals | Triple Negative Breast Neoplasms - genetics | Cell Line, Tumor | Mice | BRCA2 Protein - genetics | BRCA1 protein | DNA damage | DNA topoisomerase | Poly(ADP-ribose) polymerase | Breast cancer | Lethality | Survival | DNA repair | Bearing | Exploitation | Anticancer properties | Inhibitors | Experimental design | Cell lines | Cell cycle | Xenografts | Antitumor activity | Inhibition | Deoxyribonucleic acid--DNA | Tumors | Cancer | Index Medicus
Journal Article